That’s quite the chronicle there about the companies who decided not to bid and the ones who bid on and purchased the assets. However, that isn’t relevant to BioAmber, since they have no affiliation after the closing of the liquidation sale. It doesn’t matter how much Nextant estimated the value of the factory to be, it sold (along with the other assets) for $4.3M, and just because that $4.3M was “lower than expected” doesn’t mean there’s another transaction or recapitalization or any such thing happening.
If there was another transaction, it would have been reported clearly and directly by the monitor to the bankruptcy court/judge.
If there was a recapitalization, it would have been reported clearly and directly by the monitor to the bankruptcy court/judge.
If there was anything, any sort of magic happening that would pay the secured and unsecured creditors in full and allow some recovery to the common shareholder, it would have been reported clearly and directly by the monitor to the bankruptcy court and judge.
No “reading between lines,” no “connecting dots,” no sleuthing required. Clearly and directly.
And since they haven’t, none of that is happening. That is made up and false. In fact, clearly and directly, the monitor has stated there’ll be no recovery for the equity/shareholders.
Shareholders will lose 100% of their investment in this stock.
Market Data 
Markets 
AI
